User menu

EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2

Bibliographic reference Darcourt, Jacques ; Booij, Jan ; Tatsch, Klaus ; Varrone, Andrea ; Vander Borght, Thierry ; et. al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, no. 2, p. 443-450 (2010)
Permanent URL http://hdl.handle.net/2078.1/29646
  1. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med Mol Imaging 2002;29(10):BP30–5.
  2. Bartenstein P, Grunwald F, Kuwert T, Tatsch K, Sabri O, Benkert O, et al. Clinical applications of single photon emission tomography in neuromedicine. 1. Neuro-oncology, epilepsy, movement disorders, cerebrovascular disease. Nuklearmedizin 2000;39(7):180–95.
  3. Payoux P., Alonso M., Esquerré J.-P., Tafani M., Les « nouveaux » radiopharmaceutiques, 10.1016/j.mednuc.2008.06.007
  4. Catafau AM. Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact. Nucl Med Commun 2001;22(10):1059–60.
  5. Halldin C, Gulyas B, Langer O, Farde L. Brain radioligands – state of the art and new trends. Q J Nucl Med 2001;45(2):139–52.
  6. Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Commun 2001;22(7):819–27.
  7. DaTSCAN European Public Assessment Report. 072200en6.pdf and DaTSCAN-H-266-AR-II.pdf, http://www.emea.europa.eu/humandocs/Humans/EPAR/datscan/Datscan.htm .
  8. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15(3):503–10.
  9. Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med 1999;40(5):753–61.
  10. Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007;22(9):1229–38.
  11. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007;7:27.
  12. McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6(4):305–13.
  13. O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61(6):919–25.
  14. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78(11):1176–81.
  15. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62(2):133–40.
  16. Marek K. L., Seibyl J. P., Zoghbi S. S., Zea-Ponce Y., Baldwin R. M., Fussell B., Charney D. S., van Dyck C., Hoffer P. B., Innis R. B., [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease, 10.1212/wnl.46.1.231
  17. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15(4):692–8.
  18. Marek K., Innis R., van Dyck C., Fussell B., Early; M., Eberly S., Oakes D., Seibyl J., [123I] -CIT SPECT imaging assessment of the rate of Parkinson's disease progression, 10.1212/wnl.57.11.2089
  19. Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35(2):424–38.
  20. Yang YK, Yao WJ, Yeh TL, Lee IH, Chen PS, Lu RB, et al. Decreased dopamine transporter availability in male smokers-a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(1):274–9.
  21. Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging 2005;32(12):1452.
  22. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al.; Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004;351(24):2498–508.
  23. Varrone A, Sansone V, Pellecchia MT, Amboni M, Salvatore E, De Michele G, et al. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [(123)I]FP-CIT. Eur J Nucl Med Mol Imaging 2008;35(7):1343–9.
  24. Dobbeleir AA, Hambÿe A-SE, Franken PR. Influence of high-energy photons on the spectrum of iodine-123 with low-and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice. Eur J Nucl Med Mol Imaging 1999;26(6):655.
  25. Koch W, Hamann C, Welsch J, Popperl G, Radau PE, Tatsch K. Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies? J Nucl Med 2005;46(11):1804–11.
  26. Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J Nucl Med 2003;44(7):1184–93.
  27. Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med 1999;40(7):1091–7.
  28. Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging 2007;34(8):1240–53.
  29. Kas A, Payoux P, Habert M-O, Malek Z, Cointepas Y, El Fakhri G, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. J Nucl Med 2007;48(9):1459–67.
  30. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005;46(7):1109–18.
  31. Booij J, Busemann Sokole E, Stabin MG, Janssen AG, de Bruin K, van Royen EA. Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998;25(1):24–30.
  32. Kuikka JyrkiT., Bergstr�m KimA., Ahonen Aapo, L�nsimies Esko, The dosimetry of iodine-123 labelled 2?-carbomethoxy-3?-(4-iodophenyl)tropane, 10.1007/bf00182306
  33. Seibyl JP, Wallace E, Smith EO, Stabin M, Baldwin RM, Zoghbi S, et al. Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. J Nucl Med 1994;35(5):764–70.